Informations sur le produit
- PF-07059013PF07059013PF 07059013
PF 07059013 is a novel compound that has been shown to reduce the frequency of sickled red blood cells in a dose-dependent manner. It also reduces the levels of hemoglobin S and increases the levels of hemoglobin A2. PF 07059013 is being developed for use as an oral treatment for sickle cell disease. This drug binds to hemoglobin in the same way that hydroxyurea does, but with much higher affinity and selectivity. The molecule was optimized for clinical trials, screened against other drugs, and found to have good biochemical properties.
PF 07059013 is currently undergoing clinical trials with promising results so far.
Propriétés chimiques
Question d’ordre technique sur : 3D-BP180184 PF 07059013
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
